Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Lifestyle Intervention May Be as Effective as Medication in Japanese with Early Diabetes: DIANA Study
April 20, 2009
- CDFS to Review Japan's First Ca Blocker + ARB Combination
April 20, 2009
- Council on Regulatory Reform Calls For Continued Permission of Online Sale of OTC Drugs
April 20, 2009
- 20% of Hospitals in Shiga Pref. Prohibit Use of Generics as a Rule
April 20, 2009
- InCROM Clinical Research Unit Certified by MHRA
April 13, 2009
- Supportive Care Perspectives 2008 (SCP2008) from Synix
April 13, 2009
- R&D NEWS IN BRIEF
April 13, 2009
- Bayer to Pursue Growth Rate Twice as High as Industry Average
April 13, 2009
- FDA's Advisory Committee Recommends Approval for ONGLYZA
April 13, 2009
- Takeda Further Globalizes Its Business Structure
April 13, 2009
- Celgene to File an NDA for Lenalidomide in 2010
April 13, 2009
- Chugai Will Remain Independent Despite Acquisition of Genentech by Roche
April 13, 2009
- REGULATORY NEWS IN BRIEF
April 13, 2009
- MediciNova to Suspend All Negotiations on MN-166 for MS
April 13, 2009
- Points of Discussion on Online Sale of Drugs Listed
April 13, 2009
- Taiho Licenses Yondelis from PharmaMar
April 13, 2009
- NEW PRODUCTS
April 13, 2009
- Daiichi Sankyo to Place Top Priority on Class-1 Products
April 13, 2009
- Eisai Licenses Urief from Kissei in ASEAN Countries, India
April 13, 2009
- BUSINESS NEWS IN BRIEF
April 13, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…